← Ablatotech Vitals
Rheumatology EvidenceDigest

Efficacy of Novel Therapies for Managing Scleritis in Patients with Systemic Autoimmune Diseases

Rheumatology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 26, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Janus kinase (JAK) inhibitors represent a promising therapeutic option for refractory non-infectious scleritis associated with systemic autoimmune diseases, demonstrating efficacy in reducing ocular inflammation and improving clinical outcomes. Current evidence from prospective cohort studies suggests favorable safety profiles, though long-term data remain limited. Biologic therapies remain important alternatives, especially in pediatric populations, but JAK inhibitors may offer advantages in select cases. Careful patient selection and monitoring are essential given infection risks inherent to immunosuppression.

Clinical bottom line

Janus kinase (JAK) inhibitors represent a promising therapeutic option for refractory non-infectious scleritis associated with systemic autoimmune diseases, demonstrating efficacy in reducing ocular inflammation and improving clinical outcomes. Current evidence from prospective cohort studies suggests favorable safety profiles, though long-term data remain limited. Biologic therapies remain important alternatives, especially in pediatric populations, but JAK inhibitors may offer advantages in select cases. Careful patient selection and monitoring are essential given infection risks inherent to immunosuppression.

What the evidence shows

Scleritis in systemic autoimmune diseases often proves resistant to conventional immunosuppressive regimens, necessitating novel therapeutic approaches. Vitale et al. (2024) report on a prospective cohort from the international AIDA network registries, demonstrating that JAK inhibitors effectively reduce ocular inflammation and improve visual outcomes in patients with non-infectious inflammatory ocular diseases, including scleritis. The study highlights rapid onset of action and steroid-sparing effects, with an acceptable safety profile.

Santimov et al. (2016) review other biologic therapies used in pediatric rheumatic diseases, noting their utility in managing ocular inflammation but also emphasizing challenges such as variable response rates and infection risk. This underscores the potential role for JAK inhibitors as an alternative or adjunct in refractory cases.

Infection risk remains a critical consideration in immunosuppressed patients with systemic autoimmune diseases. Handbook chapters on bacterial and invasive fungal infections (2020) provide context on the heightened susceptibility in this population, reinforcing the need for vigilant monitoring during novel immunomodulatory therapy.

Rolfe et al. (2026) discuss international travel considerations for patients on novel immunosuppressants, including JAK inhibitors, highlighting the importance of infection prophylaxis and patient education.

Caveats and uncertainty

Data on JAK inhibitors in scleritis are primarily from observational cohorts; randomized controlled trials are lacking.

Long-term safety, particularly regarding opportunistic infections and malignancy risk, requires further elucidation.

Heterogeneity in autoimmune disease subtypes and scleritis severity complicates generalizability.

Optimal dosing regimens and treatment duration for JAK inhibitors in ocular inflammation remain to be standardized.

Comparative effectiveness versus established biologics needs clarification.

How this may change practice

JAK inhibitors may be considered for patients with refractory scleritis unresponsive to conventional immunosuppressants or biologics.

Early integration of JAK inhibitors could reduce corticosteroid exposure and associated morbidity.

Multidisciplinary collaboration between rheumatologists and ophthalmologists is essential for optimal management.

Clinicians should implement rigorous infection surveillance and patient counseling when prescribing novel therapies.

Ongoing research and registry data will inform evidence-based guidelines and personalized treatment strategies.


References

  1. Vitale A, et al. Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries. Front Med. 2024;11:1439338. DOI:10.3389/fmed.2024.1439338
  2. Santimov A, et al. Other Biological Therapies for Pediatric Rheumatic Diseases. In: Handbook of Systemic Autoimmune Diseases. 2016;Vol 13:235-250. DOI:10.1016/b978-0-444-63596-9.00024-4
  3. [Anonymous]. Bacterial infections in the lungs of patients with systemic autoimmune diseases. In: Handbook of Systemic Autoimmune Diseases. 2020;Vol 16:1-20. DOI:10.1016/b978-0-444-64217-2.00001-4
  4. Rolfe RJ, et al. International travel considerations for patients with systemic autoimmune inflammatory diseases in the era of novel immunosuppressive therapies. Rheumatol Int. 2026;46(2):345-355. DOI:10.1007/s00296-026-06224-y
  5. [Anonymous]. Invasive fungal diseases in patients with rheumatic diseases. In: Handbook of Systemic Autoimmune Diseases. 2020;Vol 16:21-40. DOI:10.1016/b978-0-444-64217-2.00002-6

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team